Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

StemCells' Phase I Trial In PMD Shows Evidence Of Progressive Myelination

RELATED NEWS
Trade STEM now with 

StemCells, Inc. (STEM: Quote) revealed preliminary evidence of progressive and durable donor-cell derived myelination in all four patients who underwent transplantation with the company's proprietary HuCNS-SC cells in its clinical trial for Pelizaeus-Merzbacher disease, or PMD, a rare hypo-myelination disorder in children.

In addition, clinical assessment disclosed small but measureable gains in motor and/or cognitive function in three of the four patients; the fourth patient remained clinically stable.

The company noted that the open-label Phase I trial enrolled four patients with the connatal form of PMD, between the ages of 14 months and 5 years, and was designed to assess safety and preliminary efficacy of the intervention. The study used magnetic resonance, or MR, imaging, commonly employed in other neurological diseases, to explore signs of myelination related to the transplanted neural stem cells.

At the one-year interval, MR imaging showed changes compatible with increased myelination in the region of the transplantation.

Further, the company said that a separate four-year observational study will continue to monitor and report the future progress for all four patients.

"The finding of myelin formation in this first exploratory study is indeed very encouraging," said Stephen Huhn, Vice President and Head of the CNS Program at StemCells, Inc. "We believe that the results of this trial provide proof-of-concept and a compelling rationale for the Company to begin planning for a controlled Phase II study in PMD. These results may also have implications for other leukodystrophies, as well as more common myelin disorders including transverse myelitis, multiple sclerosis and periventricular white matter injury seen in Cerebral Palsy..."

Register
To receive FREE breaking news email alerts for StemCells Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A ban on athletes using stamina-boosting gases - xenon and argon - came into effect on Monday. The World Anti-Doping Agency (WADA) said Hypoxia-Inducible Factor (HIF) activators Xenon and Argon have been added to the 2014 List of Prohibited Substances and Methods List following the required three-month notice period and UNESCO's communication to all States Parties. A recommendation to revise the British manufacturing growth eased further in August to its lowest level in 14 months as output and demand increased at slower rates, survey results from Markit Economics showed Monday. The Markit/CIPS Purchasing Managers' Index dropped to 52.5 from a revised 54.8 in July. Economists had expected the score to fall to 55.1 from July's original figure of 55.4. Consumers spent less in July than in the previous month, a surprise retreat that complicates the prevailing belief that the U.S. economic situation is improving. Along with the unexpected drop in spending, government figures released on Friday showed that incomes rose at a slower pace in July than in the previous month. Meanwhile, data on prices indicated that inflation pressures remain tame.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.